AAAAAA

   
Results: 1-9 |
Results: 9
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
Authors: van der Lely, AJ Hutson, RK Trainer, PJ Besser, GM Barkan, AL Katznelson, L Klibanski, A Herman-Bonert, V Melmed, S Vance, ML Freda, PU Stewart, PM Friend, KE Clemmons, DR Johannsson, G Stavrou, S Cook, DM Phillips, LS Strasburger, CJ Hacker, S Zib, KA Davis, RJ Scarlett, JA Thorner, M
Citation: Aj. Van Der Lely et al., Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist, LANCET, 358(9295), 2001, pp. 1754-1759
Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice
Authors: McCutcheon, IE Flyvbjerg, A Hill, H Li, J Bennett, WF Scarlett, JA Friend, KE
Citation: Ie. Mccutcheon et al., Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice, J NEUROSURG, 94(3), 2001, pp. 487-492
Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient
Authors: van der Lely, AJ Muller, AF Janssen, JA Davis, RJ Zib, KA Scarlett, JA Lamberts, SW
Citation: Aj. Van Der Lely et al., Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient, J CLIN END, 86(2), 2001, pp. 478-481
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant
Authors: Trainer, PJ Drake, WM Katznelson, L Freda, PU Herman-Bonert, V van der Lely, AJ Dimaraki, EV Stewart, PM Friend, KE Vance, ML Besser, GM Scarlett, JA Thorner, MO Parkinson, C Klibanski, A Powell, JS Barkan, AL Sheppard, MC Maldonado, M Rose, DR Clemmons, DR Johannson, G Bengtsson, BA Stavrou, S Kleinberg, DL Cook, DM Phillips, LS Bidlingmaier, M Strasburger, CJ Hackett, S Zib, K Bennett, WF Davis, RJ
Citation: Pj. Trainer et al., Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant, N ENG J MED, 342(16), 2000, pp. 1171-1177
Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs
Authors: Herman-Bonert, VS Zib, K Scarlett, JA Melmed, S
Citation: Vs. Herman-bonert et al., Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs, J CLIN END, 85(8), 2000, pp. 2958-2961
Biotechnology's emerging opportunities: Lessons from the Bauhaus
Authors: Scarlett, JA
Citation: Ja. Scarlett, Biotechnology's emerging opportunities: Lessons from the Bauhaus, NAT BIOTECH, 17, 1999, pp. BE13-BE15
Changes in reactivity of the digital artery of the fallow deer, Dama dama,in summer and winter
Authors: Milton, AS Carr, GA Luby, CD Scarlett, JA White, R Callingham, BA
Citation: As. Milton et al., Changes in reactivity of the digital artery of the fallow deer, Dama dama,in summer and winter, J THERM BIO, 24(5-6), 1999, pp. 465-470
Compensatory renal growth in uninephrectomized adult mice is growth hormone dependent
Authors: Flyvbjerg, A Bennett, WF Rasch, R van Neck, JW Groffen, CAH Kopchick, JJ Scarlett, JA
Citation: A. Flyvbjerg et al., Compensatory renal growth in uninephrectomized adult mice is growth hormone dependent, KIDNEY INT, 56(6), 1999, pp. 2048-2054
Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice
Authors: Flyvbjerg, A Bennett, WF Rasch, R Kopchick, JJ Scarlett, JA
Citation: A. Flyvbjerg et al., Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice, DIABETES, 48(2), 1999, pp. 377-382
Risultati: 1-9 |